INO
Price
$0.38
Change
-$0.02 (-5.00%)
Updated
Dec 6, 6:59 PM EST
97 days until earnings call
NVAX
Price
$5.58
Change
-$0.01 (-0.18%)
Updated
Dec 6, 6:59 PM EST
83 days until earnings call
Ad is loading...

Analysis and predictions INO vs NVAX

Header iconINO vs NVAX Comparison
Open Charts INO vs NVAXBanner chart's image
Inovio Pharmaceuticals
Price$0.38
Change-$0.02 (-5.00%)
Volume$1.45M
CapitalizationN/A
Novavax
Price$5.58
Change-$0.01 (-0.18%)
Volume$3.36M
CapitalizationN/A
View a ticker or compare two or three
INO vs NVAX Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
INO vs. NVAX commentary
Dec 07, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a Hold and NVAX is a Hold.

COMPARISON
Comparison
Dec 07, 2023
Stock price -- (INO: $0.38 vs. NVAX: $5.58)
Brand notoriety: INO and NVAX are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 56% vs. NVAX: 48%
Market capitalization -- INO: $111.92M vs. NVAX: $648.59M
INO [@Biotechnology] is valued at $111.92M. NVAX’s [@Biotechnology] market capitalization is $648.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • INO’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, INO is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 1 TA indicator(s) are bullish while NVAX’s TA Score has 6 bullish TA indicator(s).

  • INO’s TA Score: 1 bullish, 8 bearish.
  • NVAX’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than INO.

Price Growth

INO (@Biotechnology) experienced а +0.32% price change this week, while NVAX (@Biotechnology) price change was +0.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.65%. For the same industry, the average monthly price growth was +5.77%, and the average quarterly price growth was +27.21%.

Reported Earning Dates

INO is expected to report earnings on Mar 13, 2024.

NVAX is expected to report earnings on Feb 27, 2024.

Industries' Descriptions

@Biotechnology (+6.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for INO with price predictions.
OPEN
A.I.dvisor published
a Summary for NVAX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NVAX($649M) has a higher market cap than INO($112M). NVAX YTD gains are higher at: -45.720 vs. INO (-75.673). INO has higher annual earnings (EBITDA): -158.65M vs. NVAX (-498.29M). NVAX has more cash in the bank: 651M vs. INO (167M). INO has less debt than NVAX: INO (29.8M) vs NVAX (222M). NVAX has higher revenues than INO: NVAX (974M) vs INO (854K).
INONVAXINO / NVAX
Capitalization112M649M17%
EBITDA-158.65M-498.29M32%
Gain YTD-75.673-45.720166%
P/E RatioN/AN/A-
Revenue854K974M0%
Total Cash167M651M26%
Total Debt29.8M222M13%
FUNDAMENTALS RATINGS
INO vs NVAX: Fundamental Ratings
INO
NVAX
OUTLOOK RATING
1..100
452
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
8592
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (51) in the Medical Specialties industry is somewhat better than the same rating for NVAX (88) in the Biotechnology industry. This means that INO’s stock grew somewhat faster than NVAX’s over the last 12 months.

INO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as NVAX (100) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

INO's SMR Rating (98) in the Medical Specialties industry is in the same range as NVAX (100) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

INO's Price Growth Rating (85) in the Medical Specialties industry is in the same range as NVAX (92) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

INO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as NVAX (100) in the Biotechnology industry. This means that INO’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INONVAX
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SOPVX47.28N/A
N/A
Allspring Opportunity A
VNSYX19.13N/A
N/A
Natixis Vaughan Nelson Select Y
HWGAX15.25N/A
N/A
Hotchkis & Wiley Global Value A
PGBEX36.31N/A
N/A
Principal Blue Chip R3
GGWPX12.27N/A
N/A
Goldman Sachs Global Infras P